The use of vasodilators in the treatment of acute decompensated heart failure: Novel versus conventional therapy

James D Kirk, Deborah B. Diercks, Ezra A Amsterdam

Research output: Contribution to journalArticle

Abstract

The majority of patients who present with acute decompensated heart failure require the addition of vasodilators to adequately reduce filling pressures and improve symptoms. Conventional, therapies such as nitroglycerin and nitroprusside, although relatively effective, are difficult to use. Nesiritide, a natriuretic peptide and neurohormonal antagonist with potent vasodilator properties, may be a reasonable alternative. It offers several benefits in safety and convenience over conventional vasodilators, making it particularly suitable for both emergency department and inpatient use.

Original languageEnglish (US)
Pages (from-to)216-220
Number of pages5
JournalCritical Pathways in Cardiology
Volume3
Issue number4
DOIs
StatePublished - Dec 2004

Keywords

  • Acute decompensated heart failure
  • Emergency department
  • Natriuretic peptide
  • Neurohormonal antagonist
  • Vasodilators

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The use of vasodilators in the treatment of acute decompensated heart failure: Novel versus conventional therapy'. Together they form a unique fingerprint.

  • Cite this